Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Top Cited Papers
Open Access
- 22 February 2025
- journal article
- review article
- Published by Elsevier in Journal of Cardiac Failure
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityNew England Journal of Medicine, 2025
- Cardiovascular Outcomes with Exenatide in Type 2 Diabetes According to Ejection Fraction: The EXSCEL TrialEuropean Journal of Heart Failure, 2024
- Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialJACC, 2024
- Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsThe Lancet, 2024
- Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialThe Lancet, 2024
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesNew England Journal of Medicine, 2024
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityNew England Journal of Medicine, 2023
- Standards of Medical Care in Diabetes—2022 Abridged for Primary Care ProvidersClinical Diabetes, 2022